This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Isaacs, W. B. Articles by Ewing, C. M. Search for Related Content PubMed PubMed Citation Articles by Isaacs, W. B. Articles by Ewing, C. M.

Wild-Type p53 Suppresses Growth of Human Prostate Cancer Cells Containing Mutant p53 Alleles¹

Brady Urological Institute Laboratories, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205

Evidence supporting a broad role for the inactivation of the p53 gene in human tumorigenesis has been provided by studies showing that the p53 gene is mutated in many human cancers. In this study, we report on the mutational status of the p53 gene in prostate cancer cells and provide functional evidence that the wild-type p53 gene may have a role in suppressing prostatic tumorigenesis. Sequence analysis of exons 5–8 of the p53 gene reveals that three of five prostate cancer cell lines (TSUPr-1, PC3, DU145) contain mutations which alter the amino acid sequence of this most highly conserved portion of the gene. One of two primary prostatic cancer specimens examined also contained a mutation in this region. Transfection of the wild-type p53 gene versus a mutated p53 gene into two cell lines with p53 mutations results in reduced colony formation. Wild-type p53 gene expression is apparently incompatible with continued growth of these tumor cells inasmuch as none of the colonies which formed after wild-type transfections retain the transfected p53 sequences. Immunocytochemical data indicate that prostate carcinoma cells expressing the transfected wild-type p53 gene are growth arrested because they exhibit a reduced level of thymidine incorporation into DNA. This study is the first report of p53 gene mutations in prostate cancer cells and suggests a functional role for the p53 gene in suppressing prostatic tumorigenesis.

¹ This work was supported by NIH Grant CA 09314 and by grants from the American Cancer Society and The New York Academy of Medicine.

² To whom requests for reprints should be addressed.

Received 7/ 2/91. Accepted 7/18/91.

This article has been cited by other articles:

				E.-S. Hwang, Z. Zhang, H. Cai, D. Y. Huang, S.-M. Huong, C.-Y. Cha, and E.-S. Huang Human Cytomegalovirus IE1-72 Protein Interacts with p53 and Inhibits p53-Dependent Transactivation by a Mechanism Different from That of IE2-86 Protein J. Virol., December 1, 2009; 83(23): 12388 - 12398. [Abstract] [Full Text] [PDF]

				Y. Niu, S. Yeh, H. Miyamoto, G. Li, S. Altuwaijri, J. Yuan, R. Han, T. Ma, H.-C. Kuo, and C. Chang Tissue Prostate-Specific Antigen Facilitates Refractory Prostate Tumor Progression via Enhancing ARA70-Regulated Androgen Receptor Transactivation Cancer Res., September 1, 2008; 68(17): 7110 - 7119. [Abstract] [Full Text] [PDF]

				R. D. Dinnen, L. Drew, D. P. Petrylak, Y. Mao, N. Cassai, J. Szmulewicz, P. Brandt-Rauf, and R. L. Fine Activation of Targeted Necrosis by a p53 Peptide: A NOVEL DEATH PATHWAY THAT CIRCUMVENTS APOPTOTIC RESISTANCE J. Biol. Chem., September 14, 2007; 282(37): 26675 - 26686. [Abstract] [Full Text] [PDF]

				C.-S. Chen, Y.-C. Wang, H.-C. Yang, P.-H. Huang, S. K. Kulp, C.-C. Yang, Y.-S. Lu, S. Matsuyama, C.-Y. Chen, and C.-S. Chen Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation Cancer Res., June 1, 2007; 67(11): 5318 - 5327. [Abstract] [Full Text] [PDF]

				Z. Fabian, C. M. Csatary, J. Szeberenyi, and L. K. Csatary p53-Independent Endoplasmic Reticulum Stress-Mediated Cytotoxicity of a Newcastle Disease Virus Strain in Tumor Cell Lines J. Virol., March 15, 2007; 81(6): 2817 - 2830. [Abstract] [Full Text] [PDF]

				B. Han, H. Xie, Q. Chen, and J.-T. Zhang Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3{sigma}. Mol. Cancer Ther., April 1, 2006; 5(4): 903 - 912. [Abstract] [Full Text] [PDF]

				K. Malathi, J. M. Paranjape, E. Bulanova, M. Shim, J. M. Guenther-Johnson, P. W. Faber, T. E. Eling, B. R. G. Williams, and R. H. Silverman A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L PNAS, October 11, 2005; 102(41): 14533 - 14538. [Abstract] [Full Text] [PDF]

				W. K. Kwok, M.-T. Ling, T.-W. Lee, T. C.M. Lau, C. Zhou, X. Zhang, C. W. Chua, K. W. Chan, F. L. Chan, C. Glackin, et al. Up-Regulation of TWIST in Prostate Cancer and Its Implication as a Therapeutic Target Cancer Res., June 15, 2005; 65(12): 5153 - 5162. [Abstract] [Full Text] [PDF]

				Y. Sun and D. W. Leaman Involvement of Noxa in Cellular Apoptotic Responses to Interferon, Double-stranded RNA, and Virus Infection J. Biol. Chem., April 22, 2005; 280(16): 15561 - 15568. [Abstract] [Full Text] [PDF]

				G. Normand, P. G. Hemmati, B. Verdoodt, C. von Haefen, J. Wendt, D. Guner, E. May, B. Dorken, and P. T. Daniel p14ARF Induces G2 Cell Cycle Arrest in p53- and p21-deficient Cells by Down-regulating p34cdc2 Kinase Activity J. Biol. Chem., February 25, 2005; 280(8): 7118 - 7130. [Abstract] [Full Text] [PDF]

				D. R. Haudenschild, S. M. Palmer, T. A. Moseley, Z. You, and A. H. Reddi Bone Morphogenetic Protein (BMP)-6 Signaling and BMP Antagonist Noggin in Prostate Cancer Cancer Res., November 15, 2004; 64(22): 8276 - 8284. [Abstract] [Full Text] [PDF]

				P. V. Nantermet, J. Xu, Y. Yu, P. Hodor, D. Holder, S. Adamski, M. A. Gentile, D. B. Kimmel, S.-i. Harada, D. Gerhold, et al. Identification of Genetic Pathways Activated by the Androgen Receptor during the Induction of Proliferation in the Ventral Prostate Gland J. Biol. Chem., January 9, 2004; 279(2): 1310 - 1322. [Abstract] [Full Text] [PDF]

				K. V. Gurova, O. W. Rokhlin, A. V. Budanov, L. G. Burdelya, P. M. Chumakov, M. B. Cohen, and A. V. Gudkov Cooperation of Two Mutant p53 Alleles Contributes to Fas Resistance of Prostate Carcinoma Cells Cancer Res., June 1, 2003; 63(11): 2905 - 2912. [Abstract] [Full Text] [PDF]

				N. J. Nesslinger, X.-B. Shi, and R. W. deVere White Androgen-independent Growth of LNCaP Prostate Cancer Cells Is Mediated by Gain-of-Function Mutant p53 Cancer Res., May 1, 2003; 63(9): 2228 - 2233. [Abstract] [Full Text] [PDF]

				H. J. Knowles, R. R. Raval, A. L. Harris, and P. J. Ratcliffe Effect of Ascorbate on the Activity of Hypoxia-inducible Factor in Cancer Cells Cancer Res., April 15, 2003; 63(8): 1764 - 1768. [Abstract] [Full Text] [PDF]

				L. Xue, B. Zhou, X. Liu, W. Qiu, Z. Jin, and Y. Yen Wild-Type p53 Regulates Human Ribonucleotide Reductase by Protein-Protein Interaction with p53R2 as well as hRRM2 Subunits Cancer Res., March 1, 2003; 63(5): 980 - 986. [Abstract] [Full Text] [PDF]

				V. W. van Beusechem, P. B. van den Doel, J. Grill, H. M. Pinedo, and W. R. Gerritsen Conditionally Replicative Adenovirus Expressing p53 Exhibits Enhanced Oncolytic Potency Cancer Res., November 1, 2002; 62(21): 6165 - 6171. [Abstract] [Full Text] [PDF]

				Y.-R. Chen, J. Han, R. Kori, A.-N. T. Kong, and T.-H. Tan Phenylethyl Isothiocyanate Induces Apoptotic Signaling via Suppressing Phosphatase Activity against c-Jun N-terminal Kinase J. Biol. Chem., October 11, 2002; 277(42): 39334 - 39342. [Abstract] [Full Text] [PDF]

				L. A. Martinez, J. Yang, E. S. Vazquez, M. del Carmen Rodriguez-Vargas, M. Olive, J.-T. Hsieh, C. J. Logothetis, and N. M. Navone p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells Carcinogenesis, August 1, 2002; 23(8): 1289 - 1296. [Abstract] [Full Text] [PDF]

				B. A. Wible, L. Wang, Y. A. Kuryshev, A. Basu, S. Haldar, and A. M. Brown Increased K+ Efflux and Apoptosis Induced by the Potassium Channel Modulatory Protein KChAP/PIAS3beta in Prostate Cancer Cells J. Biol. Chem., May 10, 2002; 277(20): 17852 - 17862. [Abstract] [Full Text] [PDF]

				J. Tsubaki, V. Hwa, S. M. Twigg, and R. G. Rosenfeld Differential Activation of the IGF Binding Protein-3 Promoter by Butyrate in Prostate Cancer Cells Endocrinology, May 1, 2002; 143(5): 1778 - 1788. [Abstract] [Full Text] [PDF]

				K. Mikata, H. Uemura, H. Ohuchi, S. Ohta, Y. Nagashima, and Y. Kubota Inhibition of Growth of Human Prostate Cancer Xenograft by Transfection of p53 Gene: Gene Transfer by Electroporation Mol. Cancer Ther., February 1, 2002; 1(4): 247 - 252. [Abstract] [Full Text] [PDF]

				J. L. Shenk, C. J. Fisher, S.-Y. Chen, X.-F. Zhou, K. Tillman, and L. Shemshedini p53 Represses Androgen-induced Transactivation of Prostate-specific Antigen by Disrupting hAR Amino- to Carboxyl-terminal Interaction J. Biol. Chem., October 12, 2001; 276(42): 38472 - 38479. [Abstract] [Full Text] [PDF]

				N. M. Navone, M. d. C. Rodriguez-Vargas, W. F. Benedict, P. Troncoso, T. J. McDonnell, J.-H. Zhou, R. Luthra, and C. J. Logothetis TabBO: A Model Reflecting Common Molecular Features of Androgen-independent Prostate Cancer Clin. Cancer Res., March 1, 2000; 6(3): 1190 - 1197. [Abstract] [Full Text]

				D. F. Jarrard, S. Sarkar, Y. Shi, T. R. Yeager, G. Magrane, H. Kinoshita, N. Nassif, L. Meisner, M. A. Newton, F. M. Waldman, et al. p16/pRb Pathway Alterations Are Required for Bypassing Senescence in Human Prostate Epithelial Cells Cancer Res., June 1, 1999; 59(12): 2957 - 2964. [Abstract] [Full Text] [PDF]

				S. J. Lee, M. J. Ha, J. Lee, P. Nguyen, Y. H. Choi, F. Pirnia, W.-K. Kang, X.-F. Wang, S.-J. Kim, and J. B. Trepel Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21WAF1/CIP1 in Human Prostate Carcinoma Cells J. Biol. Chem., April 24, 1998; 273(17): 10618 - 10623. [Abstract] [Full Text] [PDF]

				M. M. Ahmed, S. F. Sells, K. Venkatasubbarao, S. M. Fruitwala, S. Muthukkumar, C. Harp, M. Mohiuddin, and V. M. Rangnekar Ionizing Radiation-inducible Apoptosis in the Absence of p53 Linked to Transcription Factor EGR-1 J. Biol. Chem., December 26, 1997; 272(52): 33056 - 33061. [Abstract] [Full Text] [PDF]

				J. Bian and Y. Sun p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: A third member of the p53 family? PNAS, December 23, 1997; 94(26): 14753 - 14758. [Abstract] [Full Text] [PDF]

				J.-K. Hwang and C.-T. Lin Co-localization of Endogenous and Exogenous p53 Proteins in Nasopharyngeal Carcinoma Cells J. Histochem. Cytochem., July 1, 1997; 45(7): 991 - 1004. [Abstract] [Full Text]

				J. Jordan, M. F. Galindo, J. H. M. Prehn, R. R. Weichselbaum, M. Beckett, G. D. Ghadge, R. P. Roos, J. M. Leiden, and R. J. Miller p53 Expression Induces Apoptosis in Hippocampal Pyramidal Neuron Cultures J. Neurosci., February 15, 1997; 17(4): 1397 - 1405. [Abstract] [Full Text] [PDF]

				W.B. Isaacs, G.S. Bova, R.A. Morton, M.J.G. Bussemakers, J.D. Brooks, and C.M. Ewing Genetic Alterations in Prostate Cancer Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 653 - 659. [Abstract] [PDF]

				J. Zimmermann, N. Lamerant, R. Grossenbacher, and P. Furst Proteasome- and p38-dependent Regulation of ERK3 Expression J. Biol. Chem., March 30, 2001; 276(14): 10759 - 10766. [Abstract] [Full Text] [PDF]

				D. R. Mercatante, C. D. Bortner, J. A. Cidlowski, and R. Kole Modification of Alternative Splicing of Bcl-x Pre-mRNA in Prostate and Breast Cancer Cells. ANALYSIS OF APOPTOSIS AND CELL DEATH J. Biol. Chem., May 4, 2001; 276(19): 16411 - 16417. [Abstract] [Full Text] [PDF]

				M. Grigorian, S. Andresen, E. Tulchinsky, M. Kriajevska, C. Carlberg, C. Kruse, M. Cohn, N. Ambartsumian, A. Christensen, G. Selivanova, et al. Tumor Suppressor p53 Protein Is a New Target for the Metastasis-associated Mts1/S100A4 Protein. FUNCTIONAL CONSEQUENCES OF THEIR INTERACTION J. Biol. Chem., June 15, 2001; 276(25): 22699 - 22708. [Abstract] [Full Text] [PDF]